Immatics Earnings Call Transcripts
Fiscal Year 2025
-
Phase I studies of IMA402 (PRAME) and IMA401 (MAGEA4/8) TCR bispecifics showed favorable safety and promising efficacy, with IMA402 achieving a 30% ORR at RP2D and durable responses in melanoma and ovarian cancer. Both agents are advancing to expansion cohorts and combination trials, targeting broad solid tumor populations.
Fiscal Year 2024
-
IMA203 demonstrated a 54% confirmed objective response rate and a median PFS of six months in heavily pretreated metastatic melanoma patients, with durable responses and a favorable safety profile. The upcoming phase III SUPREME trial will use a recommended dose of 1–10 billion TCR-T cells and focus on cutaneous and acral melanoma.
-
A mass spec-based TCR platform enables highly specific therapies, with IMA203 Gen 1 showing a 55% response rate and deep, durable responses in melanoma. A pivotal trial is set to start by year-end, with next-gen TCR-T and bispecifics data expected in H2.